Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching around $18 billion in 2020, indicating robust demand for ADHD treatments. The company reported promising data from its CTx-1301 trial in July 2023, demonstrating a significant positive effect over placebo, which highlights the potential efficacy of its product offerings. These factors contribute to a positive outlook for Cingulate's stock by showcasing a strong market opportunity and the company's advancements in developing innovative therapeutic solutions.

Bears say

Cingulate Inc has reported a significant net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which exceeds both internal estimates and consensus expectations. Furthermore, the company's financial health is threatened by substantial liquidity risks, coupled with the uncertainty surrounding the safety and efficacy of its product candidates in ongoing clinical trials. The potential hurdles include regulatory approval challenges, commercialization difficulties, and adverse shifts in investor sentiment towards the biotech sector, all of which contribute to a detrimental outlook for the company's stock.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.